-
公开(公告)号：DE69615674D1
公开(公告)日：2001-11-08
申请号：DE69615674
申请日：1996-04-18
Applicant: ABBOTT LAB
Inventor： ARENDSEN L , BAKER R , FAKHOURY A , FUNG L , GARVEY S , MCCLELLAN J , O'CONNOR J , PRASAD N , ROCKWAY W , ROSENBERG H , STEIN H , SHEN WANG , STOUT M , SULLIVAN M , AUGERI J
IPC: A61K31/195 , A61K31/215 , A61K31/38 , A61K31/381 , A61K31/41 , A61K31/4245 , A61K31/433 , A61P3/06 , A61P9/00 , A61P9/08 , A61P31/04 , A61P35/00 , A61P43/00 , C07C233/58 , C07C233/59 , C07C233/60 , C07C235/40 , C07C235/82 , C07D271/06 , C07D271/10 , C07D285/10 , C07D333/20 , A61K31/19 , A61K31/16
Abstract: The present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof, which is useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
-
Patent Agency Ranking
公开(公告)号：DE69822668T2
公开(公告)日：2005-03-10
申请号：DE69822668
申请日：1998-12-18
Applicant: ABBOTT LAB
Inventor： HOLLADAY W , ABREO A , GUNN E , LIN NAN-HORNG , GARVEY S , RYTHER KEITH , LEBOLD A , ELLIOTT L , HE YUN , WASIAK T , BAI HAO , DART J , EHRLICH P , LI YIHONG , KINCAID F , SCHKERYANTZ M , LYNCH K
IPC: A61K31/427 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04 , A61K31/40 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/50 , A61K31/505
-
公开(公告)号：DE69822668D1
公开(公告)日：2004-04-29
申请号：DE69822668
申请日：1998-12-18
Applicant: ABBOTT LAB
Inventor： HOLLADAY W , ABREO A , GUNN E , LIN NAN-HORNG , GARVEY S , RYTHER KEITH , LEBOLD A , ELLIOTT L , HE YUN , WASIAK T , BAI HAO , DART J , EHRLICH P , LI YIHONG , KINCAID F , SCHKERYANTZ M , LYNCH K
IPC: A61K31/427 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04 , A61K31/40 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/50 , A61K31/505
-
公开(公告)号：DE69813536T2
公开(公告)日：2004-02-19
申请号：DE69813536
申请日：1998-02-05
Applicant: ABBOTT LAB
Inventor： WASICAK T , GARVEY S , HOLLADAY W , LIN NAN-HORNG , RYTHER B
IPC: A61P25/04 , A61K31/422 , A61K31/4439 , A61K31/4725 , A61P25/00 , A61P43/00 , C07D487/04 , A61K31/44
Abstract: 7a-Substituted hexahydro-1H-pyrrolizine compounds having the formula wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.
-
公开(公告)号：DE69813536D1
公开(公告)日：2003-05-22
申请号：DE69813536
申请日：1998-02-05
Applicant: ABBOTT LAB
Inventor： WASICAK T , GARVEY S , HOLLADAY W , LIN NAN-HORNG , RYTHER B
IPC: A61P25/04 , A61K31/422 , A61K31/4439 , A61K31/4725 , A61P25/00 , A61P43/00 , C07D487/04 , A61K31/44
Abstract: 7a-Substituted hexahydro-1H-pyrrolizine compounds having the formula wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.
-
公开(公告)号：DE69615674T2
公开(公告)日：2002-07-11
申请号：DE69615674
申请日：1996-04-18
Applicant: ABBOTT LAB
Inventor： ARENDSEN L , BAKER R , FAKHOURY A , FUNG L , GARVEY S , MCCLELLAN J , O'CONNOR J , PRASAD N , ROCKWAY W , ROSENBERG H , STEIN H , SHEN WANG , STOUT M , SULLIVAN M , AUGERI J
IPC: A61K31/195 , A61K31/215 , A61K31/38 , A61K31/381 , A61K31/41 , A61K31/4245 , A61K31/433 , A61P3/06 , A61P9/00 , A61P9/08 , A61P31/04 , A61P35/00 , A61P43/00 , C07C233/58 , C07C233/59 , C07C233/60 , C07C235/40 , C07C235/82 , C07D271/06 , C07D271/10 , C07D285/10 , C07D333/20 , A61K31/19 , A61K31/16
Abstract: The present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof, which is useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
-
-
-
-
-
Search Results
6
records
(took 0.051 seconds)
